» Articles » PMID: 34867402

Receptor Tyrosine Kinases and Their Signaling Pathways As Therapeutic Targets of Curcumin in Cancer

Overview
Journal Front Pharmacol
Date 2021 Dec 6
PMID 34867402
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Receptor tyrosine kinases (RTKs) are transmembrane cell-surface proteins that act as signal transducers. They regulate essential cellular processes like proliferation, apoptosis, differentiation and metabolism. RTK alteration occurs in a broad spectrum of cancers, emphasising its crucial role in cancer progression and as a suitable therapeutic target. The use of small molecule RTK inhibitors however, has been crippled by the emergence of resistance, highlighting the need for a pleiotropic anti-cancer agent that can replace or be used in combination with existing pharmacological agents to enhance treatment efficacy. Curcumin is an attractive therapeutic agent mainly due to its potent anti-cancer effects, extensive range of targets and minimal toxicity. Out of the numerous documented targets of curcumin, RTKs appear to be one of the main nodes of curcumin-mediated inhibition. Many studies have found that curcumin influences RTK activation and their downstream signaling pathways resulting in increased apoptosis, decreased proliferation and decreased migration in cancer both and . This review focused on how curcumin exhibits anti-cancer effects through inhibition of RTKs and downstream signaling pathways like the MAPK, PI3K/Akt, JAK/STAT, and NF-κB pathways. Combination studies of curcumin and RTK inhibitors were also analysed with emphasis on their common molecular targets.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.


Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

Bou Antoun N, Afshan Mahmood H, Walker A, Modjtahedi H, Grose R, Chioni A Int J Mol Sci. 2025; 26(5).

PMID: 40076427 PMC: 11898767. DOI: 10.3390/ijms26051799.


Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.

Singh G, Rohit , Kumar P, Aran K Med Oncol. 2025; 42(4):97.

PMID: 40064710 DOI: 10.1007/s12032-025-02652-1.


Exploring Ketones in Chrysopogon zizanioides: A Computational Molecular Dynamic Approach to c-Met Modulation.

Sabaghan S, Srivastava R, Yadav P, Kumari M, Soni R, Beri S Mol Biotechnol. 2025; .

PMID: 39969662 DOI: 10.1007/s12033-025-01377-w.


EGF receptor in organ development, tissue homeostasis and regeneration.

Tito C, Masciarelli S, Colotti G, Fazi F J Biomed Sci. 2025; 32(1):24.

PMID: 39966897 PMC: 11837477. DOI: 10.1186/s12929-025-01119-9.


References
1.
Karagonlar Z, Koc D, Iscan E, Erdal E, Atabey N . Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016; 107(4):407-16. PMC: 4832867. DOI: 10.1111/cas.12891. View

2.
Ryan M, Sohl C, Luo B, Anderson K . The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT. Mol Cancer Res. 2018; 17(2):532-543. PMC: 6647014. DOI: 10.1158/1541-7786.MCR-18-0429. View

3.
Zhang J, Yu J, Xie R, Chen W, Lv Y . Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways. Nat Prod Res. 2015; 30(16):1858-61. DOI: 10.1080/14786419.2015.1074229. View

4.
Shao M, Zhang F, Meng G, Wang X, Xu H, Yu X . Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast. Histopathology. 2011; 59(2):264-73. DOI: 10.1111/j.1365-2559.2011.03921.x. View

5.
Huh Y, Kim S, Kim S, Chun J . Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem. 2002; 278(11):9691-7. DOI: 10.1074/jbc.M211360200. View